Xtant outlines $99M-$103M 2026 revenue guidance while integrating Dilon sales force

Organigram surges 10% on record Q3 results

Cardinal Health forecasts FY27 EPS of $12.40-$12.60 and at least $1B in share repurchases as board adds $5B to buyback authority

Bicara outlines mid-2027 interim analysis timeline as it initiates FORTIFI-FLEX and names a new CEO and CFO

Summit Midstream tightens 2026 adjusted EBITDA guidance to $235M-$255M while raising capex to $100M-$120M